Ensayos clínicos A continuación, se enumeran los ensayos clínicos actuales.517 estudios en Oncología (médica) (solo estudios abiertos). Filtra esta lista de estudios por sede, estatus, etc. Blood and Urine Identification of Methylated DNA Markers in Invasive Bladder Carcinoma Rochester, Minn. The purpose of this study is to, in tissue, discover and validate DNA methylation markers (MDMs) for detection of invasive urothelial carcinoma of the bladder. In blood, to assess the accuracy of candidate MDMs from above for detection of invasive urothelial carcinoma of the bladder. In urine, to explore the accuracy of candidate MDMs from above for detection of invasive urothelial carcinoma of the bladder. Diagnostic accuracy on urine can be compared with that on plasma using paired samples. TheraSphere With and Without Durvalumab and Tremelimumab for HCC Jacksonville, Fla. The objective of the ROWAN clinical study is to assess the the durability of local tumor control in Hepatocellular Carcinoma (HCC) patients who receive TheraSphere followed by durvalumab and tremelimumab, compared to those who receive TheraSphere treatment alone. A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM Jacksonville, Fla. The purpose of this study is to assess the safety and technical feasibility of TheraSphere GBM in patients with recurrent glioblastoma (GBM). A Phase 1, Study of BMF-500 in Adults With Acute Leukemia Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz. The purpose of this study is to evaluate the safety and tolerability of BMF-500 and to determine the OBD and RP2D of BMF-500. Screening for High Frequency Malignant Disease Rochester, Minn., La Crosse, Wis., Eau Claire, Wis. The primary objective of the study is to evaluate the sensitivity and specificity of a blood-based GuardantLUNAR-2 test to detect high frequency cancer in screen-relevant populations. Circulating Tumor DNA (cTDNA) Based in NGS (Next Generation Sequencing) Assays for Oncology Patients With Solid Tumors Rochester, Minn. The purpose of this study is to design, develop and assess the performance characteristics of NGS assays using circulating tumor DNA for the detection of mutations associated solid tumors. The performance characteristics of these assays for detecting ctDNA mutation in oncology patients will be assessed by comparing the mutation results obtained from these assays to those obtained by orthogonal methods, including tissue-based assays and results from a ctDNA assay by Guardant on blood. A Study Evaluating the Safety and Effectiveness of Therapies in Patients with Metastatic Colorectal Cancer Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this study for the Inavo + Cetux Arm (A): To evaluate the effectiveness of Inavo + Cetux in PIK3CA-mutated colorectal cancer (CRC) with no detected RAS (KRAS, NRAS) or BRAFV600E mutations. The purpose of this study for the Inavo + Bev Arm (B_: To evaluate the effectiveness Inavo + Bev in PIK3CA-mutated, RAS (KRAS, NRAS)-mutated CRC. The purpose of this study for the Atezo+SY-5069 Arm (C): To evaluate the effectiveness of atezolizumab and SY-5609 treatment combination on patients with mCRC. The purpose of this study for the GDC-6036+cetuzimab+FOLFOX Arm (E): To evaluate the effectivenss of GDC-6036 plus cetuximab plus FOLFOX on patients with mCRC. The purpose of this study for the GDC-6036 plus cetuximab Arm (F): To evaluate the effectivenss of GDC-6036 plus cetuximab on patients with mCRC. The purpose of this study for the atezolizumab plus tiragolumab or atezolizumab plus tiragolumab and bevacizumab Arm (MSI-H): To evaluate the effectivenss of atezolizumab plus tiragolumab or atezolizumab plus tiragolumab and bevacizumab. Understanding the Challenges, Behavioral Patterns, and Preferences Towards Participation in Clinical Trials in Minority Patient Populations Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz. The purpose of this study is to evaluate the challenges, behavioral patterns, and preferences of minority patient participation in clinical trials. Also, to develop and validate a personalized clinical trial educational platform to boost participation among underserved cancer patients. Safety and Efficacy Study of MLN0128 in Combination With Exemestane or Fulvestrant in Postmenopausal Women With ER/PR+ Metastatic Breast Cancer Rochester, Minn. This is a phase 1b/2 study of the safety and efficacy of MLN0128 in combination with exemestane or fulvestrant therapy in women with estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2-) advanced or metastatic breast cancer that has progressed on treatment with everolimus in combination with exemestane or fulvestrant. TRPC6 to Predict and Prevent Chemotherapy Related Cardiomyopathy and Heart Failure (Prospective Study) Jacksonville, Fla. The purpose of this study is to characterize TRPC6 risk variants for doxorubicin-related cardiotoxicity in prospectively collected samples from breast cancer patients. Breast cancer patients are more than three times at risk for developing congestive heart failure (CHF), compared with patients who did not have cancer. The increased risk of HF is observed as early as one year from diagnosis of cancer and overall, 7% of patients develop CHF (median follow-up 8.5 years) Numeración de páginas Estudios clínicos AnteriorPágina anterior Ir a página 4949 Ir a página 5050 Ir a página 5151 Ir a página 5252 SiguientePróxima página Solicite una consulta Conocimientos y categoríasInvestigación May 09, 2023 Comparte en: FacebookTwitter U.S. News & World Report reconoce a Mayo Clinic en Rochester (Minnesota), Mayo Clinic en Jacksonville (Florida) y Mayo Clinic en Phoenix y Scottsdale (Arizona) entre los mejores hospitales oncológicos del país para el período 2024-2025. Lee más sobre este gran honor. Oncología (médica)Página inicialdel departamentoSeccionesDescripción generalEnfermedades tratadasMédicosGrupos especializadosConocimientos y categoríasEnsayos clínicosInvestigaciónExperiencias en Mayo Clinic y nuestros pacientes cuentan su historiaCostos y seguroNoticias de Mayo ClinicRemisiones Investigación: los pacientes son la prioridad Mostrar la transcripción Para video Investigación: los pacientes son la prioridad [SUENA MÚSICA] Dr. Joseph Sirven, profesor de Neurología, Mayo Clinic: La misión de Mayo se centra en el paciente. La prioridad es el paciente. Aquí, la misión y la investigación se hacen para progresar en la forma de ayudar mejor al paciente y para asegurarnos de que el paciente sea la prioridad en la atención médica. De muchas maneras, esto equivale a un ciclo. Puede comenzar con algo tan simple como una idea que se desarrolla en un laboratorio, se traslada a la atención directa del paciente y, si todo sale bien y resulta útil o beneficioso, pasa a ser el método estándar. Creo que una de las características tan singulares de la forma de investigar en Mayo es la concentración en el paciente, y es lo que realmente le ayuda a captar la atención de todos. SeccionesSolicite una ConsultaDescripción generalEnfermedades tratadasMédicosGrupos especializadosConocimientos y categoríasEnsayos clínicosInvestigaciónExperiencias en Mayo Clinic y nuestros pacientes cuentan su historiaCostos y seguroNoticias de Mayo ClinicRemisiones ORG-20180179 Centros y departamentos médicos Oncología (médica)